Assessment of the Degree of Clinical Suspicion of 21-Hydroxylase Deficiency Prior to the Newborn Screening Result

Abstract

The aim of the study was to analyze the clinical suspicion and where patients were when they received the positive result of the neonatal screening for CAH 21OHD. The present data derived from a retrospective analysis of a relatively large group of patients with classical CAH 21OHD patients nosed by newborn screening in Madrid, Spain. During the period from 1990 to 2015 of this study 46 children were diagnosed with classical 21OHD [36 with the salt-wasting (SW) form and 10 with simple virilizing (SV)]. In 38 patients, the disease had not been suspected before the neonatal screening result (30 SW and 8 SV). Thirty patients (79%) were at home without suspicion of any disease, as healthy children, 3 patients (8%) were at home pending completion of the study due to clinical suspicion of any disease (ambiguous genitalia, cryptorchidism) and 5 patients (13%) were admitted to the hospital for reasons unrelated to CAH (sepsis, jaundice, hypoglycemia). It is relevant to note that 69.4% of patients (25/36) with SW form were at home with potential risk of adrenal crisis. Six females had been incorrectly labeled as male at birth. The most frequent reason for clinical suspicion was genital ambiguity in women followed by family history of the disease. Neonatal screening provided better results than clinical suspicion. In the majority of patients with 21OHD the diagnosis by screening was anticipated to the clinical suspicion of the disease even in female patients with ambiguous genitalia.

Key words

neonatal screening - congenital adrenal hyperplasia - 21-hydroxylase deficiency - salt-wasting form - simple virilizing form

Publication History

Received: 20 September 2022

Accepted after revision: 16 June 2023

Accepted Manuscript online:
16 June 2023

Article published online:
31 July 2023

• References

• 1 White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21: 245-291
• 2 Huynh T, McGown I, Cowley D. et al. The clinical and biochemical spectrum of congenital adrenal hyperplasia secundary to 21-hydroxylase deficiency. Clin Biochem Rev 2009; 30: 75-86
• 3 Riepe FG, Sippell WG. Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Rev Endocr Metab Disord 2007; 8: 349-363
• 4 Nimkarn S, Lin-Su K, New MI. Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2009; 38: 699-718
• 5 Forest MG. Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update 2004; 10: 469-485
• 6 Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005; 365: 2125-2136
• 7 New MI. Extensive clinical esperience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006; 91: 4205-4214
• 8 Pang S, Hotchkiss J, Drash AL. et al. Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay: its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1977; 45: 1003-1008
• 9 Therrell BLBS, Manter-Kapanke V, Simmank J. et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998; 101: 583-590
• 10 White PC. Neonatal screening for congenital adrenal hyperplasia. Nat Rev Endocrinol 2009; 5: 490-498
• 11 Huidobro Fernández B, Echeverria Fernández M, Dulin Iñiguez E. et al. Neonatal screening for congenital adrenal hyperplasia: transitory elevation of 17-hydroxyprogesterone. J Pediatr Endocrinol Metab 2011; 24: 155-162
• 12 Dulin-Iniguez EEM. Eguileor-Gurtubai. Programas de cribado neonatal. An Pediatr Contin 2006; 4: 61-65
• 13 Speiser PW, Azziz R, Baskin LS. et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 4133-4160
• 14 Clayton PEMW, Oberfield SE, Ritzen EM. et al. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002; 87: 4048-4053
• 15 Grosse SD, Van Vliet G. How many deaths can be prevented by newborn screening for congenital adrenal hyperplasia?. Horm Res 2007; 67: 284-291
• 16 Brosnan PG, Brosnan CA, Kemp SF. et al. Effect of newborn screening for congenital adrenal hyperplasia. Archiv Pediatr Adolesc Med 1999; 153: 1272-1278
• 17 Kovacs J, Votava F, Heinze G. et al. Lessons from 30 years of clinical diagnosis and treatment of congenital adrenal hyperplasia in five middle European countries. J Clin Endocrinol Metab 2001; 86: 2958-2964
• 18 Chu SYTW, Chen LH, Wei ML. et al. Neonatal screening for congenital adrenal hyperplasia in Taiwan: a pilot study. J Formos Med Assoc 2002; 101: 691-694
• 19 Steigert M, Schoenle EJ, Biason-Lauber A. et al. High reliability of neonatal screening for congenital adrenal hyperplasia in Switzerland. J Clin Endocrinol Metab 2002; 87: 4106-4110
• 20 Gruneiro-Papendieck LPL, Chiesa A, Bengolea S. et al. Neonatal screening program for congenital adrenal hyperplasia: adjustments to the recall protocol. Horm Res 2001; 55: 271-277
• 21 Van der Kamp HJNK, Elvers B, Van Baarle M. et al. Newborn screening for congenital adrenal hyperplasia in the Netherlands. Pediatrics 2001; 108: 1320-1324
• 22 Cartigny-Maciejewski MGN, Vanderbecken S, Gondé S. et al. Neonatal screening of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Lille experience 1980-1996. Arch Pediatr 1999; 6: 151-158
• 23 Thil'en ANA, Hagenfeldt L, von Dobeln U. et al. Benefits of neonatal screening for congenital adrenal hyperplasia (21-hydroxylase deficiency) in Sweden. Pediatrics 1998; 101: E11
• 24 Balsamo ACE, Piazzi S, Cassio A. et al. Congenital adrenal hyperplasia: neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy, 1980-1995. Pediatrics 1996; 98: 362-367
• 25 Sack JFH, Kaiserman I, Schreiber M. 21-Hydroxylase deficiency: screening and incidence in Israel. Horm Res 1997; 48: 115-119
• 26 Allen DBHG, Fitzpatrick P, Laessig R. et al. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr 1997; 130: 128-133
• 27 AL. RLMGC. Cribado neonatal de la hyperplasia suprarrenal congénita. Aplicabilidad en Galicia. Santiago de Compostela: Servicio Galego de Saude, Axencia de Avaliacion de Tecnoloxias Sanitarias de Galicia. avalia-t. 2004 Serie Avaliacion de Tecnoloxias. Informes; INF2004/03
• 28 Strnadova KA, Votava F, Lebl J. et al. Prevalence of congenital adrenal hyperplasia among sudden infant death in the Czech Republic and Austria. Eur J Pediatr 2007; 166: 1-4
• 29 Gidlof SFH, Thilen A. et al. One hundred years of congenital adrenal hyperplasia in Sweden: a retrospective, population-based cohort study. Lancet Diabetes Endocrinol 2013; 1: 35-42
• 30 Nordenström A, Ahmed S, Jones J. et al. Female preponderance in congenital adrenal hyperplasia due to CYP21 deficiency in England: implications for neonatal screening. Horm Res 2005; 63: 22-28
• 31 Liu SY, Lee CT, Tung YC. et al. Clinical characteristics of Taiwanese children with congenital adrenal hyperplasia due to 21-hydroxylase deficiency detected by neonatal screening. J Formos Med Assoc 2018; 117: 126-131